| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Evolving therapies for lower-risk myelodysplastic syndromes |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Targeting TP53 Mutations in Myelodysplastic Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
| Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
|
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
| Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
